Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2014-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jac/dku041PMID 24576950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• On‐treatment alpha‐fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir

  2014cited by this paper
• Metformin—mode of action and clinical implications for diabetes and cancer

  2014cited by this paper
• Postoperative peg‐interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus‐related hepatocellular carcinoma

  2013cited by this paper
• Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

  2013cited by this paper
• Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis.

  2013cited by this paper
• Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

  2013cited by this paper
• Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis

  2013cited by this paper
• Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?

  2013cited by this paper
• α‐fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C

  2013cited by this paper
• Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

  2012cited by this paper
• Epidemiology of viral hepatitis and hepatocellular carcinoma.

  2012cited by this paper
• High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.

  2012cited by this paper
• Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.

  2012cited by this paper
• Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer.

  2012cited by this paper
• Hepatitis D virus: an update

  2011cited by this paper
• Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.

  2011cited by this paper
• Management of hepatocellular carcinoma: An update

  2011cited by this paper
• Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma.

  2011cited by this paper
• Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.

  2010cited by this paper
• Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

  2010cited by this paper
• Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.

  2009cited by this paper
• Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

  2009cited by this paper
• Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.

  2008cited by this paper
• Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

  2008cited by this paper
• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

  2006cited by this paper
• The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

  2006cited by this paper
• Antiviral options for the treatment of chronic hepatitis B.

  2006cited by this paper
• Lamivudine for patients with chronic hepatitis B and advanced liver disease.

  2004cited by this paper
• Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis

  2003cited by this paper
• A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C

  2003cited by this paper
• A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts

  2000cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• Decreasing hepatitis D virus infection in Taiwan: An analysis of contributory factors

  1997cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper

• Environmental exposures and the risk of hepatocellular carcinoma

  2025cites this paper
• A Novel Nomogram Model for Predicting the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection

  2025cites this paper
• Liver Cancer: Progress and Priorities.

  2024cites this paper
• High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs

  2024cites this paper
• Baseline viral load and on-treatment hepatocellular carcinoma risk in chronic hepatitis B: A multinational cohort study.

  2024cites this paper
• Predictive Risk Factors and Scoring Systems Associated with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B

  2024cites this paper
• Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.

  2024cites this paper
• Epidemiological, diagnostic, therapeutic and prognostic impact of hepatitis B and D virus infection on hepatocellular carcinoma: A review of the literature.

  2024cites this paper
• Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy.

  2023cites this paper
• Comparative effectiveness of tenofovir versus entecavir in patients with hepatitis B virus-related cirrhosis in Taiwan: a retrospective cohort study

  2023cites this paper
• Presence of diabetes further heightens hepatocellular carcinoma risk in patients with hepatitis B or hepatitis C virus-related cirrhosis: A meta-analysis

  2023cites this paper
• Research Progress on Prognosis Evaluation and Clinical Application of aMAP Score in Patients with Chronic Liver Disease

  2023cites this paper
• Assessment of Serum Aldo-Keto Reductase Family 1 Member B10 for Early Diagnosis of Hepatocellular Carcinoma Patients in Suez Canal University Hospital, Egypt ‎

  2023cites this paper
• Advancements in the Diagnosis of Hepatocellular Carcinoma

  2023cites this paper
• Hepatocellular carcinoma: Review of the literature

  2022cites this paper
• Predictive Role for Serum Aldo-Keto Reductase Family1 Member B10 for Early Detection of Hepatocellular Carcinoma in Egyptian Patients

  2022influential citation
• Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores

  2022cites this paper
• Hepatitis B Virus-Associated Hepatocellular Carcinoma

  2022cites this paper
• Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?

  2022cites this paper
• Epidemiology, mutational landscape and staging of hepatocellular carcinoma.

  2021cites this paper
• External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy

  2021cites this paper
• An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.

  2021cites this paper
• Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: When and how?

  2021cites this paper
• Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures

  2021cites this paper
• Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. Viral

  2021cites this paper
• Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis

  2020cites this paper
• Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir

  2020cites this paper
• Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta‐analysis

  2020cites this paper
• Is tenofovir more effective than entecavir to prevent hepatocellular carcinoma? The controversy goes on

  2020cites this paper
• Hepatitis B virus‐related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non‐viral risk factors

  2020cites this paper
• Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review

  2020cites this paper
• Epidemiology of Hepatocellular Carcinoma

  2020cites this paper
• Epidemiology and Management of Hepatocellular Carcinoma.

  2019cites this paper
• Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.

  2019cites this paper
• Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent

  2019cites this paper
• Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis

  2019cites this paper
• Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.

  2018influential citation
• Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti‐viral therapy in patients with chronic hepatitis B

  2018cites this paper
• Stratification of hepatocellular carcinoma risk through modified FIB‐4 index in chronic hepatitis B patients on entecavir therapy

  2018cites this paper
• A combination of the on‐treatment FIB‐4 and alpha‐foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir

  2018cites this paper
• Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir

  2018cites this paper
• Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients

  2017cites this paper
• Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure

  2017cites this paper
• Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.

  2017cites this paper
• Unmet Needs in Clinical and Basic Hepatitis B Virus Research

  2017cites this paper
• Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir

  2017cites this paper
• Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

  2016cites this paper
• Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.

  2016cites this paper
• Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.

  2015cites this paper
• The impact of anti-HBV treatment on the occurrence and recurrence of hepatocellular carcinoma: focus on Asian studies.

  2015cites this paper